Lingmin Zhang

Dr. Lingmin Zhang

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2017 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
PWPeng Wang
Peng Wang
LZLingmin Zhang
Lingmin Zhang
WZWenfu Zheng
Wenfu Zheng
LCLiman Cong
Liman Cong
ZGZhaorong Guo
Zhaorong Guo
XJXingyu Jiang
Xingyu Jiang

25 May 2017 in ACS Nano
Verified
Journal Article
Closed access
XYXinglong Yang
Xinglong Yang
JYJunchuan Yang
Junchuan Yang
LWLe Wang
Le Wang
BRBei Ran
Bei Ran
YJYuexiao Jia
Yuexiao Jia
XJXingyu Jiang
Xingyu Jiang

25 April 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
YLYifeng Lei
Yifeng Lei
LTLixue Tang
Lixue Tang
YXYangzhouyun Xie
Yangzhouyun Xie
Yunlei XianyuYunlei Xianyu
Yunlei Xianyu
LZLingmin Zhang
Lingmin Zhang
XJXingyu Jiang
Xingyu Jiang
Pancreatic cancer is one of the deadliest human cancers, whose progression is highly dependent on the nervous microenvironment. The suppression of gene expression of nerve growth factor (NGF) may have great potential in pancreatic cancer treatment. Here we show that gold nanocluster-assisted delivery of siRNA of NGF (GNC–siRNA) allows efficient NGF gene silencing and pancreatic cancer treatment. The GNC–siRNA complex increases the stability of siRNA in serum, prolongs the circulation lifetime of siRNA in blood and enhances the cellular uptake and tumour accumulation of siRNA. The GNC–siRNA complex potently downregulates the NGF expression in Panc-1 cells and in pancreatic tumours, and effectively inhibits the tumour progression in three pancreatic tumour models (subcutaneous model, orthotopic model and patient-derived xenograft model) without adverse effects. Our study constitutes a straightforward but effective approach to inhibit pancreatic cancer via NGF knockdown, suggesting a promising therapeutic direction for pancreatic cancer.

27 October 2017 in NPG Asia Materials
Verified
Journal Article
Open access
LZLingmin Zhang
Lingmin Zhang
PWPeng Wang
Peng Wang
QFQiang Feng
Qiang Feng
NWNuoxin Wang
Nuoxin Wang
ZCZitian Chen
Zitian Chen
XJXingyu Jiang
Xingyu Jiang
The emerging CRISPR/Cas9 system represents a promising platform for genome editing. However, its low transfection efficiency is a major problem hampering the application of the gene-editing potential of CRISPR/Cas9. Herein, by screening a pool of more than 56 kinds of agents, we constructed a novel polyethylene glycol phospholipid-modified cationic lipid nanoparticle (PLNP)-based delivery system that can condense and encapsulate a Cas9/single-guide RNA (sgRNA) plasmid (DNA) to form a core–shell structure (PLNP/DNA) that mediated up to 47.4% successful transfection of Cas9/sgPLK-1 plasmids in A375 cells in vitro. An intratumor injection of Cas9/sgPLK-1 plasmids into melanoma tumor-bearing mice resulted in significant downregulation of Polo-like kinase 1 (PLK-1) protein and suppression of the tumor growth (>67%) in vivo. This approach provides a versatile method that could be used for delivering the CRISPR/Cas9 system with high efficiency and safety both in vitro and in vivo.

7 September 2017 in Advanced Science
Verified
Journal Article
Open access
PDF file
PWPeng Wang
Peng Wang
LZLingmin Zhang
Lingmin Zhang
YXYangzhouyun Xie
Yangzhouyun Xie
NWNuoxin Wang
Nuoxin Wang
RTRongbing Tang
Rongbing Tang
XJXingyu Jiang
Xingyu Jiang
The type II bacterial clustered, regularly interspaced, short palindromic repeats (CRISPR)‐Cas9 (CRISPR‐associated protein) system (CRISPR‐Cas9) is a powerful toolbox for gene‐editing, however, the nonviral delivery of CRISPR‐Cas9 to cells or tissues remains a key challenge. This paper reports a strategy to deliver Cas9 protein and single guide RNA (sgRNA) plasmid by a nanocarrier with a core of gold nanoclusters (GNs) and a shell of lipids. By modifying the GNs with HIV‐1‐transactivator of transcription peptide, the cargo (Cas9/sgRNA) can be delivered into cell nuclei. This strategy is utilized to treat melanoma by designing sgRNA targeting Polo‐like kinase‐1 (Plk1) of the tumor. The nanoparticle (polyethylene glycol‐lipid/GNs/Cas9 protein/sgPlk1 plasmid, LGCP) leads to >70% down‐regulation of Plk1 protein expression of A375 cells in vitro. Moreover, the LGCP suppresses melanoma progress by 75% on mice. Thus, this strategy can deliver protein‐nucleic acid hybrid agents for gene therapy.

18 July 2019 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
LZLingmin Zhang
Lingmin Zhang
LWLe Wang
Le Wang
YXYangzhouyun Xie
Yangzhouyun Xie
PWPeng Wang
Peng Wang
SDSai Deng
Sai Deng
XJXingyu Jiang
Xingyu Jiang